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Introduction: The aim of this study was to evaluate, for the first time, the differences in gene expression profiles of
normal and osteoarthritic (OA) subchondral bone in human subjects.
Methods: Following histological assessment of the integrity of overlying cartilage and the severity of bone
abnormality by micro-computed tomography, we isolated total RNA from regions of interest from human OA
(n = 20) and non-OA (n = 5) knee lateral tibial (LT) and medial tibial (MT) plateaus. A whole-genome profiling study
was performed on an Agilent microarray platform and analyzed using Agilent GeneSpring GX11.5. Confirmatory
quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis was performed on samples from
9 OA individuals to confirm differential expression of 85 genes identified by microarray. Ingenuity Pathway Analysis
(IPA) was used to investigate canonical pathways and immunohistochemical staining was performed to validate
protein expression levels in samples.
Results: A total of 972 differentially expressed genes were identified (fold change≥ ± 2, P ≤0.05) between
LT (minimal degeneration) and MT (significant degeneration) regions from OA samples; these data implicated
279 canonical pathways in IPA. The qRT-PCR data strongly confirmed the accuracy of microarray results (R2 = 0.58,
P <0.0001). Novel pathways were identified in this study including Periostin (POSTN) and Leptin (LEP), which are
implicated in bone remodeling by osteoblasts.
Conclusions: To the best of our knowledge, this study represents the most comprehensive direct assessment to
date of gene expression profiling in OA subchondral bone. This study provides insights that could contribute to the
development of new biomarkers and therapeutic strategies for OA.Introduction
Osteoarthritis (OA) is the most prevalent musculoskeletal
disorder and the most common form of arthritis among
older individuals in most countries worldwide; OA consti-
tutes a large economic burden due to the associated costs
of medical care and lost wages [1,2]. Although degene-
ration of cartilage is the major characteristic of OA, the
disease also involves the entire joint organ, including
structural modifications of underlying subchondral bone,
pathological changes of the meniscus and synovitis [3,4].* Correspondence: mikelee@src.riken.jp
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reproduction in any medium, provided the orMaintenance of normal joint structure and function relies
on load adaptation of the cartilage and bone. Disruption
of the physiological relationship between these tissues
contributes to the development of OA pathology [5].
Increasing evidence indicates that the subchondral
bone, consisting of the subchondral plate and subchon-
dral spongiosa, plays a major role in the initiation and
progression of OA [6]. Magnetic resonance imaging-
based visualization of the whole knee structure demon-
strates that increased tibial subchondral bone volume is
associated with severity of knee OA [7]. Kraus and col-
leagues demonstrated that subchondral bone texture can
be used as a biomarker to predict progression of knee
OA [8]. A study comparing two guinea pig strains indi-
cates that an increasing rate of knee subchondral bone
remodeling is associated with the process of cartilagetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies have shown that factors released from bone cells
might affect cartilage metabolism [10,11]. These studies
provide insights into a temporal relationship between
subchondral structural changes and alterations in articu-
lar cartilage during the development of OA; they also
underscore the importance of elucidating the molecular
changes in human subchondral bone to improve our un-
derstanding of the pathogenesis of OA.
Whole-genome microarray is a common technology
for studying the behavior of many genes simultaneously.
All of the gene expression microarray profiling studies
in OA so far have been performed on human articular
cartilage, meniscus or synovium; however, none have
been performed on human subchondral bone tissue dir-
ectly. Only one study has reported the gene expression
profiles of subchondral bone in an early OA experimen-
tal mouse model [12]. A few studies have evaluated the
gene expression profiles of distal trabecular bone from
human OA [13,14], but this site is remote from sub-
chondral bone rather than a reflection of alterations
locally in the OA joint. This paucity of subchondral bone
microarray studies is most probably due to the difficul-
ties associated with isolation of high-quality RNA from
subchondral bone. As described in our previous study
[15], we have developed a method of precisely harvesting
specific regions of subchondral bone tissue and for
subsequently isolating high-quality RNA from these
specimens. Our methodology has made it possible to
perform microarray analyses of human subchondral
bone samples.
Our goal in this study was to evaluate the association
of subchondral bone gene expression with bone histo-
morphometry at sites of intact articular cartilage and
osteoarthritic lesioned cartilage. To our knowledge, this
is the first study to successfully perform microarray ana-
lyses of human knee subchondral bone in OA and non-
OA samples, thereby providing clues to the pathogenic
mechanisms of OA that could inform development of
new diagnostic markers and therapeutic targets.
Methods
Human knee joint tissues
Human osteoarthritic tibial plateaus with medial compart-
ment dominant OA and macroscopically normal lateral
compartments were obtained during total knee joint re-
placement surgery from knee OA patients. The diagnosis
of OA was based on the criteria for knee OA of the Ameri-
can College of Rheumatology [16]. Normal tibial plateaus
were obtained at autopsy or within 8 hours after amputa-
tion surgery from donors with nonarthritic knee joints.
To ensure consistency of sampling of prespecified re-
gions of interest, the anatomic orientation was indicated
on the freshly isolated specimens by marker pen andthen all specimens were stored immediately in liquid
nitrogen. Methods for precisely obtaining specimens of a
particular type from specific regions of interest of the
joint have been described previously [15]. The tissues
were manipulated at all times under liquid nitrogen to
prevent RNA degradation. Regions of interest were har-
vested for histological analysis of the articular cartilage,
and subchondral bone structural parameters were deter-
mined by micro-computed tomography; regions imme-
diately adjacent were harvested for RNA isolation and
microarray analysis. For microarrays, RNA was isolated
from subchondral bone from four regions: the outer and
inner lateral tibial (LT) plateau and the inner and central
medial tibial (MT) plateau (Additional file 1). The gene
expression intensities changed little within the LT plateau
(between inner and outer LT regions) and within the MT
plateau (inner and central MT regions) (Additional file 2);
we therefore based the analyses in the current study on a
comparison of gene expression from subchondral bone of
20 outer LT plateaus and 20 MT plateaus from knee OA
specimens. These 40 samples were derived from 30 indi-
vidual knee OA specimens, yielding 10 paired LT and MT
samples and 10 unpaired LT and MT samples. The 40 OA
samples chosen for microarray analysis represented a sub-
set from our previous study [15], and were chosen to have
LT OARSI scores ≤8 and MT OARSI scores ≥18. In
addition, five LT and five MT paired subchondral bone
samples from non-OA donors were used as controls for
the microarray analysis. The characteristics of the samples
used for microarray analysis are summarized in Table 1
and Additional file 3.
The study was approved by the institutional review
board of Academia Sinica, Tri-Service General Hospital
and Taipei Medical University Hospital, and written in-
formed consent was obtained from all of the participants.
Subchondral bone tissue harvest and RNA isolation
All tissues were sectioned to generate osteochondral slabs 2
to 2.5 mm thick from regions of interest for micro-
computed tomography scanning and histological analysis
(Figure 1); regions immediately adjacent were isolated for
subsequent grinding and RNA isolation using a custom-
made workstation as described previously [15]. Appro-
ximately 100 mg powdered subchondral bone from the tib-
ial plateau was obtained for RNA extraction. Five milliliters
of Trizol (Invitrogen, Carlsbad, CA, USA) were added to
100 mg (dry weight) ground tissue powder and mixed by
vortexing until homogeneous. A total of 1 ml chloroform
was added to the homogenized sample and centrifuged at
12,000 × g for 15 minutes at 4°C to achieve phase sepa-
ration. The clear aqueous phase was transferred to a
fresh tube for a second phase separation with phenol/
chloroform/isoamyl alcohol (25:24:1; Sigma-Aldrich, St.
Louis, MO, USA), followed by RNA precipitation with pure
Table 1 Characteristics of the samples used for microarray analysis
Osteoarthritis Nonosteoarthritis
Characteristic LT MT LT MT
OARSI 4.7 ± 1.34 20.8 ± 1.62* 3.00 ± 1.85 3.75 ± 1.67
BV/TV (mm3) 21.32 ± 7.47 65.39 ± 12.61* 24.41 ± 3.71 35.26 ± 10.12
SMI 1.56 ± 0.34 −1.69 ± 1.70* 0.99 ± 0.21 0.68 ± 0.73
Tb.Th (mm) 0.18 ± 0.04 0.36 ± 0.09* 0.19 ± 0.01 0.26 ± 0.08
Tb.N (1/mm) 1.16 ± 0.27 1.83 ± 0.33* 1.28 ± 0.21 1.36 ± 0.09
Tb.Sp (mm) 0.51 ± 0.12 0.25 ± 0.09* 0.56 ± 0.09 0.49 ± 0.03
Age (years) 71.10 ± 9.55 69.65 ± 9.55 38.40 ± 13.45 38.40 ± 13.45
Male sex (%) 33 34 36 32
Number 20 20 5 5
Values presented as mean ± standard deviation. BV/TV, percent bone volume; LT, lateral tibial; MT, medial tibial; OARSI, histological scoring system to grade
severity of osteoarthritis; SMI, structure model index; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness. *P <0.001 considered
significant comparing MT osteoarthritis versus LT osteoarthritis. P values were determined by two-tailed unpaired Student’s t test.
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pellet was dissolved in RNase-free water and genomic
DNA was removed by DNase digestion (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
To further improve RNA quality, one-half volume of
7.5 M LiCl (Invitrogen) was added and incubated at −20°C
for at least 30 minutes followed by RNA precipitation
by centrifugation at 12,000 × g for 15 minutes. After
70% ethanol washing, the RNA was resuspended in
RNase-free water. The RNA concentration and purity
were determined by Nano-Drop (NanoDrop Technologies,
Wilmington, DE, USA). The RNA integrity number
and the 28 s/18 s ratio were estimated using RNA 6000Figure 1 Sites of micro-computed tomography analysis and regions c
(osteoarthritis (OA)) and (B) normal knee tibial plateau (non-OA). Red dashe
chosen for micro-computed tomography and histological analysis at the tw
subchondral bone from the lateral tibial (LT) and medial tibial (MT) plateauNano Assays on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) according to the
manufacturer’s instructions.Microarray analysis
Four hundred nanograms of total RNA per sample were
used for one round of cRNA synthesis and amplification.
Cyanine 3-labeled cRNA was then purified and hybri-
dized to Agilent whole human genome 44 k microarray
chips (Agilent Technologies). All procedures were car-
ried out according to the manufacturer’s instructions
(Agilent Technologies, Taipei, Taiwan). The array signalhosen for RNA isolation. (A) Human osteoarthritic knee tibial plateau
d boxes, regions chosen for RNA isolation; black boxes, regions
o regions of interest. (C) Representative three-dimensional images of
from OA and non-OA specimens.
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Spring GX software (version 11.5; Agilent Technologies).
Gene expression values of all datasets were normalized
using quantile normalization; probes with low signal in-
tensities were excluded by setting the filter above 32.
The normalized values were log transformed. Significant
differentially expressed genes between lateral and medial
samples in OA patients were identified using an adjusted
Student’s t test (P <0.05) corrected for multiple compa-
risons with the Benjamini–Hochberg test. The results
were used to run principal component analysis to un-
cover the trends among OA and normal samples. Dif-
ferentially expressed genes between medial and lateral
regions among groups were identified by a threshold
of ≥2 fold-change and P ≤0.05. The hierarchical clus-
tering method, with Euclidean distance and centroid
linkage, was further applied to cluster the differences in
gene expression levels between samples. Lists of dif-
ferentially expressed genes were imported into ingenuity
pathway analysis (IPA; Ingenuity Systems, Redwood City,
CA, USA) to identify functional annotations and bio-
logical interactions from the many known relationships
between proteins, genes and diseases. The biological
interaction scores were defined by the IPA statistical
algorithm based on its knowledge base, and the adjusted
P value was calculated by Fisher’s exact test and cor-
rected for multiple comparisons with the Benjamini–
Hochberg test. All microarray raw data are available
through the GEO database [GEO:GSE51588].
Quantitative reverse-transcription polymerase chain
reaction validation
To validate results from microarray analysis, we per-
formed reverse-transcription polymerase chain reaction
(qRT-PCR) for 85 genes (plus GAPDH) on nine additional
OA paired LT and MT subchondral bone specimens; eight
of these additional OA knee joint specimens have been
described previously [15], as well as the qRT-PCR results
for some of the genes combined with data yielded from
one additional knee OA specimen. Forty-three of these
genes were identified for verification on the basis of sig-
nificant fold-change (≥2) comparing LT and MT micro-
array results. The remaining 42 genes were identified on
the basis of their potential involvement in OA as des-
cribed previously [15]. The expression of these 42 genes
was previously analyzed for seven regions of interest from
eight OA cartilage and subchondral bone specimens.
In the current study, we analyzed two regions of interest
(LT and MT subchondral bone corresponding to outer LT
and center MT of the prior work) in nine specimens (the
eight former specimens and an additional OA specimen
with available LT and MT regions). The qRT-PCR was per-
formed using the Taqman high-density microfluidic cards
(Invitrogen, Carlsbad, CA) according to the manufacturer’sinstructions. RNA from each region was converted into
cDNA using Superscript III reverse transcriptase (Invitro-
gen, Carlsbad, CA). The qRT-PCR reactions were per-
formed on the ABI Prism 7900HT Sequence Detection
system and the fluorescent signal intensity was analyzed
by Sequence Detector v2.3 software (Applied Biosystems,
Foster City, California). The levels of cDNA among sam-
ples were normalized to the expression of GAPDH and an-
alyzed with the ΔΔCt relative quantification method to
identify significant variation in gene expression comparing
LT and MT regions in OA samples. Two-tailed unpaired
Student t tests were performed to evaluate for statistically
significant differences in gene expression levels between
regions.
Immunohistochemistry staining
Approximately 2 mm diameter sections from the tibial
plateau were fixed in 4% paraformaldehyde (Sigma-
Aldrich) overnight and decalcified in 10% ethylenedia-
mine-N, N, N′, N′-tetraacetic acid, disodium salt, dehydrate
(Sigma-Aldrich) for 2 weeks. After decalcification, the sec-
tions were embedded in paraffin and 10 μm sections were
prepared. The embedded tissue sections were then depa-
raffinized, hydrated, and the endogenous peroxidase activity
was quenched in 0.3% H2O2–methanol for 30 minutes.
After incubating in 0.5% trypsin/1% CaCl2 at 37°C for
30 minutes and blocking with diluted goat serum at 25°C
for 1 hour, the sections were incubated with anti-human
PSOTN (dilution 1:300) antibodies (ab14041; Abcam,
Cambridge, MA, USA), and LEP (dilution 1:1,000) anti-
bodies (ab16627; Abcam) or nonimmune goat serum at
4°C overnight and reacted with biotinylated secondary anti-
body for 30 minutes. Signal amplification and staining were
performed using Vectastain ABC kits (Vector Laboratory,
Burlingame, CA, USA) according to the manufacturer’s
protocol and counterstained with hematoxylin solution Gill
no. 3 (Sigma-Aldrich).
Results
Analysis of differential gene expression
For the microarray analysis, 972 differentially expressed
genes with ≥2 fold-changes between OA MT and OA LT
regions were identified; 420 of these genes were upregu-
lated and 552 were downregulated in OA MT compared
with OA LT (Additional file 4). In total, 640 genes were
differentially expressed with greater than twofold expres-
sion level changes (308 upregulated and 332 downre-
gulated), 163 genes with changes greater than threefold
(65 upregulated and 98 downregulated), 111 genes with
changes greater than fourfold (28 upregulated and 83
downregulated), 35 genes with changes greater than
sixfold (11 upregulated and 24 downregulated), and 23
genes with changes greater than eightfold (eight upregu-
lated and 15 downregulated) (Figure 2A). A graphical
depiction of microarray gene expression results across
Figure 2 Microarray analyses of gene expression of osteoarthritis and non-osteoarthritis of subchondral bone and qRT-PCR validation
in osteoarthritis knee subchondral bone. (A) Differentially expressed genes were classified based on their expression levels with a minimum of
twofold, threefold, fourfold, sixfold, and eightfold changes. (B) Unsupervised hierarchical clustering of osteoarthritis (OA) and non-OA samples was
performed for genes whose differential expression exceeded twofold (972 genes). Distances between samples were detected with a Euclidean
algorithm and clustered with a centroid linkage method. The OA medial tibial (MT) samples (gray) were clustered together and clearly separated
from the OA lateral tibial (LT) (brown) and non-OA samples. Non-OA LT samples (N-LT, red) and non-OA MT samples (N-MT, blue) were clustered
together with OA LT samples. (C) Eighty-five genes (plus GAPDH) were selected for quantitative reverse-transcription polymerase chain reaction
(qRT-PCR) validation on a separate group of nine OA subchondral bone specimens. The results of qRT-PCR were strongly consistent with those of
microarray analysis (R2 = 0.5764, P <0.0001). FC, fold-change.
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seen in Additional file 4.
Unsupervised hierarchical clustering was performed
on the differentially expressed genes to identify thegroups or clusters of genes based on similarities between
the expression profiles of the samples. On the basis of
gene expression profiles, OA LT and OA MT samples
were grouped into two distinct clusters. However, the
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was mixed and did not cluster by sample site; the clus-
tering of all non-OA samples was more akin to the OA
LT samples than to the OA MT samples (Figure 2B).
Quantitative reverse-transcription polymerase chain
reaction validation
Nine joint tissue samples were available for validation of
microarray results; qRT-PCR analysis of LT and MT sub-
chondral bone regions of these samples was performed on
86 selected genes with GAPDH as endogenous control.
Based on the results of histological evaluation and micro-
computed tomography scanning, the subchondral bone
samples selected from the OA MT regions displayed cha-
racteristics of severe stages of OA; whereas the OA LT
regions displayed characteristics of relatively normal
joints. The mean expression pattern of the LT region was
compared with the mean expression pattern of MT re-
gions. By qRT-PCR, 77 of 85 genes showed a statistically
significant difference between regions (Additional file 5).
Expression by qRT-PCR matched the pattern (upre-
gulation or downregulation) of expression observed by
microarray, and the two datasets were strongly correlated
(R2 = 0.5764, P <0001; Figure 2C). The most differentially
upregulated genes in OA MT regions were IL11, POSTN,
ASPN, COL6A3, TUBB3, COL3A1, OGN, DIO2, PPEF1,
and TNFSF11. The most differentially downregulated
genes in OA MT regions were LEP, APOB, ADH1B,
CCL8, TUSC5, KLB, NPR3, PLIN1, PCK1, and MYO16.
All of these genes were validated by qRT-PCR except for
ADH1B and MYO16, because these two genes were not
available on the microfluidic cards used for qRT-PCR
(Table 2).
Functional and pathway analysis
IPA of gene expression profiles revealed 279 functional
networks (canonical pathways) (Additional file 6) that
were significantly associated with the differentially ex-
pressed genes. The predominant associated networks and
biological functions were related to lipid metabolism and
mineral metabolism (Additional files 7 and 8), connective
tissue disorders, cellular growth and proliferation, connect-
ive tissue development and function (Additional file 9).
Most of these pathways were associated with OA patho-
genesis such as bone remodeling, adiposity, connective
tissue, and cell activity and death (Table 3). Interestingly,
on performing pathway analysis with the most upregu-
lated and downregulated genes, a novel signaling network
in OA was identified; this network was generally cha-
racterized by upregulation of bone mineralization or
collagen-associated genes, such as COL3A1 (upregulated
7.33-fold, ranking sixth in the top upregulated gene list),
COL6A3 (upregulated 8.27-fold, ranking fourth in the top
upregulated gene list), BMP1, BMP7, POSTN (upregulated15.65-fold, ranking second in the top upregulated gene
list), WISP1, HTRA1, SOST, and ITGA11, and the down-
regulation of genes associated with cellular metabolism,
proliferation or differentiation (NMB, LEP (downregulated
23.27-fold, ranking first in the top downregulated gene
list), CHRDL2, GRB14, CIDEC, CIDEA, BTG2, PLAC8,
and PRDM16). Additional differentially expressed genes in
this network included ANGPTL1 (upregulated 2.16-fold),
which is involved in angiogenesis. Both POSTN and LEP
may affect the phosphorylation of AKT signaling
(Figure 3A).
Validation of protein expression in subchondral bone
specimens
The regions of interest of subchondral bone samples
ground for the gene expression study were about 5 mm
deep under the calcified cartilage, which included the sub-
chondral bone plate and subarticular spongiosa. These
regions have a very heterogeneous complement of cells,
including osteoblasts, osteoclasts, osteocytes and bone
marrow cells. Although the specific cell types contributing
to the changes in gene expression cannot easily be con-
firmed, all of the cell types in the subchondral bone would
be expected to contribute to the subchondral bone gene
expression profile. To obtain further independent valid-
ation of the microarray results, immunohistochemical
staining was performed to investigate the protein expres-
sion of proteins Periostin and Leptin corresponding to
genes POSTN and LEP in human OA and non-OA tissue
sections from LT and MT regions. The highly expressed
Periostin could be found in osteoblasts beneath the tide-
mark, in osteocytes, and in lining cells of the OA MT re-
gions, but not OA LT regions (Figure 3B,C). Protein
expression of Leptin was low in OA MT regions, but
strong in OA LT regions (Figure 3D,E). By immunohisto-
chemical analysis, the proteins Periostin and Leptin were
not differentially expressed in the MT and LT regions of
non-OA samples (Additional file 10).
Discussion
To the best of our knowledge, this represents the first
comprehensive whole genome expression profiling of
non-OA and OA subchondral bone. The validity of the
microarray results was confirmed by qRT-PCR for a se-
lected subset of genes. Based on analysis by IPA, we
identified biological functions implicated in the patho-
genesis of OA in bone. Many of the functional networks
identified in this study were also associated with pro-
cesses in connective tissue development and function.
In our previous study [15], we evaluated the expres-
sion of 61 OA genes and correlated the expression pat-
terns with the bone morphometric measurement (bone
volume). The expression of a total of 45 of 61 genes in
the subchondral bone was significantly correlated with
Table 2 Top ten upregulated and downregulated genes comparing lateral tibial bone (below intact cartilage) with
medial tibial bone (below lesioned cartilage)











Genes with increased expression in medial tibial bone
NM_000641 IL11 Interleukin-11 1.32 × 10–14 16.02 1.12 110.31*
NM_006475 POSTN Periostin, osteoblast specific factor 1.48 × 10–10 15.65 1.55 9.68*
NM_017680 ASPN Asporin 2.82 × 10–9 9.04 2.93 6.34*
NM_057165 COL6A3 Collagen, type VI, alpha 3 9.65 × 10–10 8.27 1.33 5.11*
NM_006086 TUBB3 Tubulin, beta 3 6.98 × 10–15 7.36 1.11 6.28*
NM_000090 COL3A1 Collagen, type III, alpha 1 5.33 × 10–16 7.33 1.32 6.45*
NM_033014 OGN Osteoglycin 7.24 × 10–10 6.69 1.70 9.33*
NM_013989 DIO2 Deiodinase, iodothyronine, type II 1.58 × 10–11 6.20 1.31 5.74*
NM_006240 PPEF1 Protein phosphatase, EF-hand calcium
binding domain 1
5.31 × 10–13 6.14 1.97 4.51*
NM_003701 TNFSF11 Tumor necrosis factor (ligand) superfamily,
member 11
1.21 × 10–11 5.90 1.07 2.64*
Genes with decreased expression in medial tibial bone
NM_000230 LEP Leptin 4.00 × 10–10 −23.27 −2.05 −18.99*
NM_000384 APOB Apolipoprotein B 3.31 × 10–10 −16.88 −2.12 −10.20*
NM_000668 ADH1B Alcohol dehydrogenase 1B (class I),
beta polypeptide
2.27 × 10–7 −12.23 −1.95 NA
NM_005623 CCL8 Chemokine (C–C motif) ligand 8 8.17 × 10–9 −10.50 −1.59 −6.00*
NM_172367 TUSC5 Tumor suppressor candidate 5 4.22 × 10–10 −10.25 −1.89 −8.19*
NM_175737 KLB Klotho beta 2.24 × 10–8 −10.00 −1.63 −6.09*
NM_001204375 NPR3 Natriuretic peptide receptor C 1.36 × 10–10 −9.95 −1.38 −7.81*
NM_002666 PLIN1 Perilipin 1 2.98 × 10–8 −9.60 −1.81 −5.88*
NM_002591 PCK1 Phosphoenolpyruvate carboxykinase 1 1.03 × 10–9 −9.01 −1.87 −5.44*
NM_001198950 MYO16 Myosin XVI 5.81 × 10–7 −8.84 −1.93 NA
LT, lateral tibial; MT, medial tibial; NA, not analyzed; OA, osteoarthritis. aAdjusted P value for microarray corrected for multiple testing by the Benjamini–Hochberg
method. *P <0.001 for quantitative reverse-transcription polymerase chain reaction (qRT-PCR), comparing OA MT versus OA LT. P values were determined by two-
tailed unpaired Student’s t test.
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ASPN, BMP6, BMPER, CCL2, CCL8, COL5A1, COL6A3,
COL7A1, COL16A1, FRZB, GDF10, MMP3, OGN, OMD,
POSTN, PTGES, TNFSF11, WNT1 and others, including
the ratio of OPG (also known as TNFRSF11B) to RANKL
(also known as TNFSF11). RANKL is primarily produced
from osteocytes, osteoblasts and/or marrow stromal cells
and is a key factor for osteoclast differentiation and acti-
vation. RANKL binds to OPG, also known as osteo-
clastogenesis inhibitory factor, and interacts with the
receptor (RANK) for RANKL, to modulate the level of
osteoclast activity and regulate bone homeostasis in re-
sponse to various endocrine, paracrine, cytokine and
mechanical stresses [17,18]. As shown in Additional file 11,
significant correlations were observed for OPG/RANKL
and the bone parameters including percent bone volume,
bone structure (structure model index), trabecular thick-
ness and trabecular space. These data confirmed ourhypothesis that investigations of subchondral bone gene
expression changes could provide clues to the pathogenic
mechanisms of OA and inform development of new diag-
nostic markers and therapeutic targets. We focused on the
outer LT and central MT regions for the purposes of com-
prehensive microarray analyses in the current study. The
characteristics of the central MT region generally included
cartilage matrix loss, cyst formation within cartilage
matrix, denuded sclerotic bone, and thickened subchon-
dral bone plate, consistent with a bone sclerosis phenotype
[19], whereas the outer LT region was relatively normal.
Many of the most significantly regulated genes identified
by this microarray study have documented roles in the
pathogenesis of OA, arthritis or bone formation including
seven of the top 10 upregulated genes (POSTN, ASPN,
COL6A3, COL3A1, OGN, DIO2, TNFSF11) and two of
the top 10 downregulated genes (LEP, APOB) [20-27].
Through IPA we could also identify the involvement of a
Table 3 Genes representative of gene clusters associated with osteoarthritis
Functional annotation
(number of genes, P value)a













NM_004370 COL12A1 Collagen, type XII, alpha 1 6.55 × 10–08 2.26 1.01 1.76
(42 genes, P = 1.5 × 10–6) NM_000594 TNF Tumor necrosis factor 1.17 × 10–08 −3.17 −1.45 −3.42*
Abnormal morphology
of collagen fibrils
NM_000093 COL5A1 Collagen, type V, alpha 1 2.63 × 10–08 2.90 1.35 6.40*
(7 genes, P = 1.68 × 10–6) NM_000393 COL5A2 Collagen, type V, alpha 2 2.34 × 10–10 3.12 1.40 3.18
Adiposity (24 genes, P <10–7) NM_003394 WNT10B Wingless-type MMTV
integration site Family,
member 10B
9.76 × 10–09 2.05 −1.08 NA
NM_001279 CIDEA Cell death-inducing DFFA-like
effector a
2.74 × 10–09 −6.26 −1.71 NA
Bone mineral density NM_025237 SOST Sclerostin 2.59 × 10–04 2.51 1.44 4.77*
(21 genes, P = 1.1 × 10–5) NM_005357 LIPE Lipase, hormone-sensitive 4.46 × 10–09 −8.71 −1.73 −4.21*
Angiogenesis NM_004673 ANGPTL1 Angiopoietin-like 1 2.55 × 10–06 2.16 1.02 NA
(69 genes, P <10–7) NM_002982 CCL2 Chemokine (C–C motif)
ligand 2
3.08 × 10–05 −3.76 −1.31 −4.87*
Osteoarthritis NM_001851 COL9A1 Collagen, type IX, alpha 1 1.42 × 10–06 2.19 −1.05 2.35
(23 genes, P <10–7) NM_001463 FRZB Frizzled-related protein 1.36 × 10–10 −3.69 1.38 −7.72*
Proliferation of cells NM_001004439 ITGA11 integrin, alpha 11 4.05 × 10–10 2.31 −1.03 NA
(303 genes, P <10–7) NM_021077 NMB Neuromedin B 1.14 × 10–06 −3.00 −1.36 NA
NM_004490 GRB14 Growth factor receptor-
bound protein 14
3.38 × 10–12 −3.20 −1.18 NA
NM_006763 BTG2 BTG family, member 2 9.11 × 10–08 −3.67 −1.31 NA
Quantity of connective tissue NM_003474 ADAM12 ADAM metallopeptidase
domain 12
1.86 × 10–10 2.30 1.10 1.93
(48 genes, P <10–7) NM_022094 CIDEC Cell death-inducing DFFA-like
effector c
2.08 × 10–07 −6.09 −1.63 NA
Differentiation of cells NM_054034 FN1 Fibronectin 1 1.44 × 10–07 2.19 1.38 2.10*
(175 genes, P <10–7) NM_016619 PLAC8 Placenta-specific 8 1.01 × 10–08 −2.28 1.14 NA
Cell movement NM_000094 COL7A1 Collagen, type VII, alpha 1 2.25 × 10–09 2.28 −1.00 3.81*
(176 genes, P <10–7) NM_012193 FZD4 Frizzled family receptor 4 3.62 × 10–10 −3.02 −1.37 4.93*
Necrosis NM_080838 WISP1 WNT1 inducible signaling
pathway protein 1
3.79 × 10–08 2.50 1.09 NA
(218 genes, P <10–7) NM_004797 ADIPOQ Adiponectin, C1Q and
collagen domain containing
1.71 × 10–07 −6.63 −1.69 10.51*
Mineralization of cells NM_001719 BMP7 Bone morphogenetic
protein 7
1.65 × 10–09 2.50 1.34 2.26**
(14 genes, P = 3 × 10–6) NM_015424 CHRDL2 Chordin-like 2 1.40 × 10–04 −4.04 1.38 −15.71*
LT, lateral tibial; MT, medial tibial; NA, not analyzed; OA, osteoarthritis. aNumber of genes associated with the particular ingenuity pathway and differentially
expressed in MT versus LT regions of OA samples by microarray analysis; P value calculated by Fisher’s exact test. bAdjusted P value for microarray corrected for
multiple testing by the Benjamini–Hochberg method. *P <0.001 and **P <0.05 for quantitative reverse-transcription polymerase chain reaction (qRT-PCR); P <0.05
was considered significant comparing OA MT versus OA LT. P values determined by two-tailed unpaired Student’s t test.
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http://arthritis-research.com/content/15/6/R190lipid metabolism protein network and a mineral metabo-
lism protein network that involved 29 and 22 differentially
expressed genes respectively; these networks included
PLINE, LIPE, DGAT2, ADRB1, NPY1R, HCAR3 and
P2RRY14 that changed −9.6-fold, –8.7-fold, –7.8-fold,
–6.2-fold, –7.4-fold, –5.1-fold, and −5.1-fold respectivelycomparing OA MT with OA LT (Additional files 7 and 8).
These functional networks indicated that the bone cells in
the OA MT regions were characterized by a condition of
low energy production that included a low rate of mineral
metabolism. These results are compatible with a low rate
of bone remodeling in MT regions.
Figure 3 Prediction of an interactive network of genes and validation of protein expression in osteoarthritis subchondral bone.
(A) Network analysis was performed on differentially expressed genes in the osteoarthritis (OA) samples by ingenuity pathway analysis (IPA).
Relationship labels: A, activated; P, phosphorylation/dephosphorylation. (B), (C), (D), (E) Antibodies against proteins Periostin and Leptin
corresponding to genes POSTN and LEP were used to detect protein expression (dark brown staining) by immunohistochemistry of OA
subchondral bone. Highly expressed, Periostin could be found in osteoblasts (OB) under the tidemark (TM), in osteocytes (OC) and in lining cells
(LC) in the OA medial tibial (MT) regions, but not in the OA lateral tibial (LT) regions. Leptin could barely be detected in the OA MT regions, but
was strongly expressed in the OA LT regions. All sections were counterstained light blue with hematoxylin. Scale bar = 0.2 mm.
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http://arthritis-research.com/content/15/6/R190Increased bone remodeling is an important predictor of
OA progression [8] and is characteristic of early stages of
OA including resorption of bone and increased porosity in
the subchondral bone region [28]. Given that OA MT re-
gions of interest could be defined as representing late stages
of OA, we were interested to determine whether OA LT re-
gions of interest could be described as representing early
stages of OA. The OARSI histopathological scores of all OA
LT samples were <6, representing a relatively intact overlying
cartilage matrix with minimal superficial fibrillation not too
dissimilar from normal. However, in contrast to normal sam-
ples, the bone structural parameters of the OA LT regions
had a lower bone volume, thinning of the subchondral bone
plate, increased porosity in the subchondral region and re-
duced bone density (bone density data not shown) suggestive
of early OA. Another indicator of early OA, as demonstrated
by animal models of OA and in OA patients, is increased
bone remodeling characterized by a decreased expression ra-
tio of OPG to RANKL [29,30]. In contrast to non-OA tissues,
a reduced OPG to RANKL ratio was identified in OA LT re-
gions compared with non-OA LT regions (OPG lacked sig-
nificant change, but RANKL was upregulated 1.63-fold, one-tailed unpaired Student t test P= 0.048), consistent with
early OA. Thus, based on the bone parameters and OPG
to RANKL ratios, comparing LT with non-OA we con-
cluded that the bone gene expression patterns of OA LT
regions were consistent with an early-stage OA phenotype.
According to a hypothetical model of OA pathogenesis
proposed by Burr and Gallant [6], joint loading increases
bone remodeling in the early stage of OA, and a bone–
cartilage crosstalk may occur via diffusion of small mole-
cules or increased vascularization at the deep layers of
cartilage that could interfere with the normal collagen net-
work. These changes would lead to a loss of aggrecan, in-
creasing inflammation, and result in bone sclerosis at late
stages of OA. Several of the genes identified in this study
fit nicely into this hypothetical model. For instance, upre-
gulation of SOST was identified (2.51-fold); SOST is an
inhibitor of Wnt signaling that responds to mechanical
loading in the proximal rat tibia and is associated with
bone mass changes [31]. In addition, several genes rele-
vant to cell differentiation and activity of osteoblasts,
osteoclasts and osteocytes were identified in both a mouse
load-regulated gene expression model [32] and in this
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osteoblast collagen mineralization), WNT5A (agonist of
WNT signaling pathway in osteoblasts and osteocytes)
and VCAN (regulating transforming growth factor beta
expression in osteoclasts). These findings suggest that
mechanical loading plays an important role in structural
changes of human subchondral bone, initiates bone re-
modeling, and contributes to the pathogenesis of OA.
Moreover, our results could provide a possible novel mo-
lecular mechanism to explain changes in bone remodeling
during OA development based on an AKT-regulated net-
work. AKT is a serine/threonine-specific protein kinase
that plays a pivotal role in many cellular processes such as
metabolism, apoptosis, cell proliferation, transcription, cell
migration and extracellular matrix alternation [33]. In an
early-stage of OA, overexpressed LEP may increase phos-
phorylation of AKT [34], which will trigger the down-
stream signaling pathway to increase bone remodeling. In
a late stage of OA, upregulated POSTN may inhibit phos-
phorylation of AKT [35] and will decrease the cellular me-
tabolism, cell proliferation, and differentiation; the rate of
bone remodeling would thereby decline.
One of the limitations of this study was that the sub-
chondral bone samples were obtained from OA joints at
end-stage disease due to the difficulty of obtaining joints
with early stages of OA from humans. However, compa-
ring our results with the gene expression profiles of sub-
chondral bone in an early OA experimental mouse model
[12], their reported fold-changes in SB gene expression of
ASPN, CCL2, COL3A1, COL5A1, POSTN and TNFSF11
at the initial stages of OA were similar to those of our
study. This result strongly supports the credibility of this
study. Another limitation was the difficulty distinguishing
whether differentially expressed genes reflected OA pro-
gression in cartilage, differences in innate bone structure,
or were driven by changes in mechanical loading. In our
currently study, significant correlation between overlying
cartilage integrity and underlying subchondral bone struc-
tural parameters could be identified (Additional file 12),
suggesting that differential gene expression across the sub-
chondral bone is due, at least in part, to differences in
cartilage integrity of the LT and MT regions in OA.
Microarray analysis of additional non-OA control samples
could help to exclude differentially expressed genes driven
by innate bone structure. However, to exclude genes
driven by mechanical loading, microarray analysis of
lateral compartment dominant OA is necessary.
The site of initiation of OA, at bone or cartilage, has
been disputed for decades. Numerous clinical and ex-
perimental studies have confirmed that increased bone
volume and changes in bone quality of the tibial subchon-
dral bone of the knee are related to loss of cartilage integ-
rity [7,8,36-38]. Goldring and Goldring have pointed out
that subchondral bone responds more rapidly to adverseloading and events than cartilage [5]. Moreover, the integ-
rity of subchondral bone predicts later worsening of radio-
graphic osteoarthritis progression [8]. As summarized by
Martel-Pelletier and Pelletier, an abnormal rate of bone re-
modeling, incomplete bone mineralization and increased
osteoid collagen matrix will result in hypomineralization of
subchondral bone and deterioration of cartilage as mani-
fested by knee OA progression [39]. These data would sug-
gest that drugs designed to target both the bone and
cartilage compartments to optimize bone remodeling rates
and inhibit cartilage loss in the early stages of OA could in-
hibit progression of disease. The recent success of strontium
ranelate as a disease-modifying agent for OA provides the
first clear evidence that this hypothesis has been confirmed
[40]. Some other bone-targeting agents have been assessed
as OA therapeutics, including bisphosphonates [41,42], calci-
tonin [43] and vitamin D [44]. These bone-acting agents are
unlikely to be effective in late stages of OA, when remodeling
is already suppressed. The development of diagnostic bio-
markers to detect progressive changes in early stages of OA
is therefore important. The genes highly regulated in early
stages of OA in our microarray data could provide potential
diagnostic biomarkers or therapeutic targets for OA.
Conclusion
Our microarray results were obtained by examining early
and late stages of OA and non-OA samples. Most of the
differentially expressed genes in bone are involved in car-
tilage and bone development, OA pathogenesis and bone
remodeling in the early and late stages of OA. This direct
assessment of gene expression profiling in OA subchon-
dral bone provides a comprehensive understanding of dis-
ease pathology that could further the development of new
OA biomarkers and therapeutic strategies.
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